Dupilumab Benefits Shown in Phase 3 Prurigo Nodularis Trials ...Middle East

Medscape - News
The results "support the involvement of type 2 cytokines in driving PN disease pathogenesis and the targeting of the IL-4/IL-13 axis as a novel therapeutic paradigm" for PN, the authors write. MDedge News

Hence then, the article about dupilumab benefits shown in phase 3 prurigo nodularis trials was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Dupilumab Benefits Shown in Phase 3 Prurigo Nodularis Trials )

Apple Storegoogle play

Last updated :

Also on site :